About this trial
Glycemic imbalances are very common in shock patients admitted to intensive care units. A blood glucose control every 2 hours is routinely performed in patients requiring insulin therapy. In practice, we use a protocol and management software called "CPG" (Personalized Control of Blood Glucose). This involves taking capillary samples from the fingertips. In addition to the pain generated, local haematomas and sensitivity disorders have been described. Night-time sampling also leads to repeated awakenings. The "CGM GUARDIAN 2" system has been validated for the measurement of glucose in interstitial fluid in insulin-dependent diabetic patients. An electrode is placed on the patient's abdomen or arm for up to 6 days. This electrode consists of a needle that is inserted subcutaneously only during the placement. The sugar level is read using a sensor placed on the electrode and an insulin pump (which will not deliver therapy (for our study) and which will be used only as an information reader to know the glucose level and trends). Interstitial fluid is automatically drawn from the electrode every minute and averaged every 5 minutes.
This device has not yet been validated in resuscitation patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient in septic shock
Arterial hypotension requiring noradrenaline
Hyperglycaemia requiring insulin therapy
Disqualifiers
Patients under guardianship, curatorship or deprived of liberty
Pregnant or breastfeeding women
Trial design
Single group
Treatments tested in this trial
CGM GUARDIAN 2
Devicecontinuous blood glucose monitoring system
Treatment groups
Trial outcomes
Primary outcomes
Glucose level
Sponsors and contacts
Click on the lead sponsor to view all of their trials.